Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (421-430 of 566) with videos related to

Pageof 57
Sort By:
American Journal of Hematology|April 17, 2018
Time to plateau as a predictor of survival in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Blood Cancer Journal|December 12, 2023
Muscle and fat composition in patients with newly diagnosed multiple myelomaNadine H Abdallah, Hiroki Nagayama, Naoki Takahashi, et al.
Blood Advances|August 21, 2023
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapyCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
American Journal of Hematology|September 30, 2017
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)Nidhi Tandon, Surbhi Sidana, Angela Dispenzieri, et al.
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Frontiers in Endocrinology|July 8, 2022
Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal OutcomeEli Muchtar, Matthew T Drake, Nelson Leung, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 19, 2022
The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow upNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 3, 2015
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantationNelson Leung, Shaji K Kumar, Siobhan V Glavey, et al.
Pageof 57

Showing results (421-430 of 566) with videos related to

Sort By:
Pageof 57
American Journal of Hematology|April 17, 2018
Time to plateau as a predictor of survival in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Blood Cancer Journal|December 12, 2023
Muscle and fat composition in patients with newly diagnosed multiple myelomaNadine H Abdallah, Hiroki Nagayama, Naoki Takahashi, et al.
Blood Advances|August 21, 2023
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapyCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
American Journal of Hematology|September 30, 2017
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)Nidhi Tandon, Surbhi Sidana, Angela Dispenzieri, et al.
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Frontiers in Endocrinology|July 8, 2022
Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal OutcomeEli Muchtar, Matthew T Drake, Nelson Leung, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 19, 2022
The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow upNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 3, 2015
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantationNelson Leung, Shaji K Kumar, Siobhan V Glavey, et al.
Pageof 57